Skip to main content

Advertisement

SpringerLink
Log in

EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2

  • Guidelines
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

The guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The aims of the guidelines are to assist nuclear medicine practitioners in making recommendations, performing, interpreting and reporting the results of clinical dopamine D2 receptor SPECT or PET studies, and to achieve a high quality standard of dopamine D2 receptor imaging, which will increase the impact of this technique in neurological practice.

The present document is an update of the first guidelines for SPECT using D2 receptor ligands labelled with 123I [1] and was guided by the views of the Society of Nuclear Medicine Brain Imaging Council [2], and the individual experience of experts in European countries. The guidelines intend to present information specifically adapted to European practice. The information provided should be taken in the context of local conditions and regulations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tatsch K, Asenbaum S, Bartenstein P, et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine transporter ligands. Eur J Nucl Med Mol Imaging. 2002;29:BP30–5.

    Article  CAS  PubMed  Google Scholar 

  2. Society of Nuclear Medicine Brain Imaging Council. Ethical clinical practice of functional brain imaging. J Nucl Med. 1996;37:1256–9.

    Google Scholar 

  3. Elsinga PH, Hatano K, Ishiwata K. PET tracers for imaging of the dopaminergic system. Curr Med Chem. 2006;13:2139–53.

    Article  CAS  PubMed  Google Scholar 

  4. Mukherjee J, Yang ZY, Das MK, Brown T. Fluorinated benzamide neuroleptics – III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol. 1995;22:283–96.

    Article  CAS  PubMed  Google Scholar 

  5. Schreckenberger M, Hagele S, Siessmeier T, et al. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging. 2004;31:1128–35.

    Article  CAS  PubMed  Google Scholar 

  6. Farde L, Ehrin E, Eriksson L, et al. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci U S A. 1985;82:3863–7.

    Article  CAS  PubMed  Google Scholar 

  7. Lindsey KP, Gatley SJ. Applications of clinical dopamine imaging. Neuroimaging Clin N Am. 2006;16:553–73, vii–viii

    Article  PubMed  Google Scholar 

  8. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology. 2005;64:208–15.

    CAS  PubMed  Google Scholar 

  9. Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. Neuroimage. 2004;23:1–16.

    Article  CAS  PubMed  Google Scholar 

  10. Booij J, Knol RJ. SPECT imaging of the dopaminergic system in (premotor) Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(Suppl 3):S425–8.

    Article  PubMed  Google Scholar 

  11. Halldin C, Gulyas B, Langer O, Farde L. Brain radioligands – state of the art and new trends. Q J Nucl Med. 2001;45:139–52.

    CAS  PubMed  Google Scholar 

  12. Pinborg LH, Videbaek C, Knudsen GM, et al. Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion. Synapse. 2000;36:322–9.

    Article  CAS  PubMed  Google Scholar 

  13. Knudsen GM, Karlsborg M, Thomsen G, et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging. 2004;31:1631–8.

    Article  CAS  PubMed  Google Scholar 

  14. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry. 2002;73:517–23.

    Article  CAS  PubMed  Google Scholar 

  15. Oyanagi C, Katsumi Y, Hanakawa T, et al. Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodobenzofuran single-photon emission computed tomography. J Neuroimaging. 2002;12:316–24.

    Article  PubMed  Google Scholar 

  16. Kim YJ, Ichise M, Ballinger JR, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord. 2002;17:303–12.

    Article  PubMed  Google Scholar 

  17. Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson’s disease. Brain. 1997;120(Pt 12):2187–95.

    Article  PubMed  Google Scholar 

  18. Pirker W, Asenbaum S, Wenger S, et al. Iodine-123-epidepride-SPECT: studies in Parkinson’s disease, multiple system atrophy and Huntington’s disease. J Nucl Med. 1997;38:1711–7.

    CAS  PubMed  Google Scholar 

  19. Plotkin M, Amthauer H, Klaffke S, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm. 2005;112:677–92.

    Article  CAS  PubMed  Google Scholar 

  20. Pani L, Pira L, Marchese G. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur Psychiatry. 2007;22:267–75.

    Article  PubMed  Google Scholar 

  21. Scherer J, Tatsch K, Schwarz J, Oertel W, Kirsch MC, Albus M. Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics. Biol Psychiatry. 1994;36:627–9.

    Article  CAS  PubMed  Google Scholar 

  22. Klemm E, Grunwald F, Kasper S, et al. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Am J Psychiatry. 1996;153:183–90.

    CAS  PubMed  Google Scholar 

  23. Ichise M, Toyama H, Fornazzari L, Ballinger JR, Kirsh JC. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington’s disease. J Nucl Med. 1993;34:1274–81.

    CAS  PubMed  Google Scholar 

  24. Ginovart N, Lundin A, Farde L, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington’s disease. Brain. 1997;120(Pt 3):503–14.

    Article  PubMed  Google Scholar 

  25. Oertel WH, Tatsch K, Schwarz J, et al. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson’s disease. Ann Neurol. 1992;32:743–8.

    Article  CAS  PubMed  Google Scholar 

  26. Muhr C. Positron emission tomography in acromegaly and other pituitary adenoma patients. Neuroendocrinology. 2006;83:205–10.

    Article  CAS  PubMed  Google Scholar 

  27. Heiss WD, Herholz K. Brain receptor imaging. J Nucl Med. 2006;47:302–12.

    CAS  PubMed  Google Scholar 

  28. Rinne JO, Hietala J, Ruotsalainen U, et al. Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C]raclopride. J Cereb Blood Flow Metab. 1993;13:310–4.

    CAS  PubMed  Google Scholar 

  29. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153–8.

    Article  CAS  PubMed  Google Scholar 

  30. Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging. 2007;34:1240–53.

    Article  PubMed  Google Scholar 

  31. Popperl G, Radau P, Linke R, Hahn K, Tatsch K. Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism. Nucl Med Commun. 2005;26:39–43.

    Article  PubMed  Google Scholar 

  32. Radau PE, Linke R, Slomka PJ, Tatsch K. Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med. 2000;41:220–7.

    CAS  PubMed  Google Scholar 

  33. Zubal IG, Early M, Yuan O, Jennings D, Marek K, Seibyl JP. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson’s disease patients. J Nucl Med. 2007;48:857–64.

    Article  PubMed  Google Scholar 

  34. Buchert R, Berding G, Wilke F, et al. IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies. Eur J Nucl Med Mol Imaging. 2006;33:1073–83.

    Article  CAS  PubMed  Google Scholar 

  35. Slifstein M, Hwang DR, Martinez D, et al. Biodistribution and radiation dosimetry of the dopamine D2 ligand 11C-raclopride determined from human whole-body PET. J Nucl Med. 2006;47:313–9.

    CAS  PubMed  Google Scholar 

  36. Verhoeff NP, Sokole EB, Stabin M, et al. Dosimetry of iodine-123 iodobenzamide in healthy volunteers. Eur J Nucl Med. 1993;20:747–52.

    CAS  PubMed  Google Scholar 

  37. Votaw JR, Ansari MS, Mason NS, et al. Dosimetry of iodine-123-epidepride: a dopamine D2 receptor ligand. J Nucl Med. 1995;36:1316–21.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The members of the ENC acknowledge the role of the following persons (in alphabetical order) for their advice and contribution to this and the previous guidelines: S. Asenbaum, M. Bardiés, A. Bischof Delaloye, R. Boellaard, P. Bartenstein, A. Catafau, L. Friberg, C. Halldin, M. Nowak Lonsdale, L. Pilowsky, A. Pupi and M. Seppänen, as well as the EANM Dosimetry and Physics Committee.

Disclaimer

These guidelines summarize the views of the Neuroimaging Committee of the EANM and reflect recommendations for which the EANM cannot be held responsible. The recommendations should be taken in the context of good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions. The guidelines have been brought to the attention of the National Societies of Nuclear Medicine.

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, University Hospital Leuven, Herestraat 49, 3000, Leuven, Belgium

    Koen Van Laere

  2. Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institute, Stockholm, Sweden

    Andrea Varrone

  3. Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

    Jan Booij

  4. Nuclear Medicine Division, Université Catholique de Louvain, Mont-Godinne Medical Center, Yvoir, Belgium

    Thierry Vander Borght

  5. Clinical Neurophysiology Unit, San Martino Hospital, University of Genoa, Genova, Italy

    Flavio Nobili

  6. Department of Nuclear Medicine, Gazi University, Ankara, Turkey

    Özlem L. Kapucu

  7. Psychiatry, Department of Mental Health Sciences, University College London, London, UK

    Zuzana Walker

  8. Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

    Kjell Någren

  9. Department of Nuclear Medicine, Municipal Hospital of Karlsruhe Inc, Karlsruhe, Germany

    Klaus Tatsch

  10. Nuclear Medicine Division, Centre Antoine Lacassagne and University Hospital, Université de Nice Sophia Antipolis, Nice, France

    Jacques Darcourt

Authors
  1. Koen Van Laere
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Varrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jan Booij
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thierry Vander Borght
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Flavio Nobili
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Özlem L. Kapucu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zuzana Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kjell Någren
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Klaus Tatsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jacques Darcourt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koen Van Laere.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van Laere, K., Varrone, A., Booij, J. et al. EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. Eur J Nucl Med Mol Imaging 37, 434–442 (2010). https://doi.org/10.1007/s00259-009-1265-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-009-1265-z

Keywords

Search

Navigation